Noripurum

Quick links to important sections

Noripurum

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noripurum

Quick Facts

Property Description
Active ingredient Iron(III) Hydroxide Polymaltose Complex (IHP)
Form Oral solution, Syrup, Chewable tablets, Injectable solution
Pharmacological class Antianemic drug, Hematinic
Common use Iron deficiency and related anemia
Origin Synthetic macro-molecular complex

What is Noripurum: Definition and Pharmacological Class

Noripurum is a brand name for a pharmaceutical preparation classified as an antianemic drug and hematinic, primarily used to address deficiencies in the body's iron stores. The preparation's general purpose is to provide supplemental iron, which is an essential element for correcting states of iron deficiency and supporting the vital function of hemoglobin synthesis. The active ingredient, Iron(III) Hydroxide Polymaltose Complex (IHP), is recognized as an agent for iron replacement therapy. This classification indicates its medically recognized role in the clinical management of iron-related conditions.

Composition and Nature: Iron Polymaltose Complex

The sole active component of Noripurum is the Iron(III) Hydroxide Polymaltose Complex, a synthetic macro-molecular complex where the essential mineral Iron(III) is bound to polymaltose, a carbohydrate structure. A distinctive feature of this composition is that the iron remains in a stable, non-ionic state, reducing its chemical reactivity in the gastrointestinal system compared to traditional ionic iron salts. Noripurum is differentiated by the variety of high-level dosage forms it offers, including an oral solution and syrup, chewable tablets, and an injectable solution.

Non-Ionic Iron Delivery and General Benefit

The specific composition of the Iron Polymaltose Complex facilitates a principle of controlled iron delivery and targeted absorption by the body, which is a key characteristic. This structure allows the iron to be released gradually and specifically absorbed. The general benefit of this non-ionic delivery system is the efficient replenishment of necessary iron stores, supporting hemoglobin synthesis without the high concentration of unabsorbed free iron in the gut, which often results in common gastrointestinal discomforts associated with older iron compounds. The general benefit is the provision of bioavailable iron in a well-tolerated formulation.

Regulatory References

  1. Antianemic Drugs
  2. Hematinics
  3. Macromolecular Complexes
  4. PubChem CID 148119
  5. Nonionic Iron in IPC
  6. Syrups
  7. Injections
  8. Controlled Iron Delivery
  9. Drug Absorption

What side effects are possible with Noripurum?

Possible Side Effects and Safety Information

The official documentation of safety characteristics for Iron(III) Hydroxide Polymaltose Complex (Noripurum) is based on classifications defined by government regulatory authorities.


Classification of Adverse Reactions

The majority of documented adverse reactions relate to the gastrointestinal system and are classified as uncommon (occurring in fewer than 1 in 100 people). These may include nausea, abdominal pain, vomiting, constipation, diarrhea, and a feeling of fullness. Reactions involving the skin and subcutaneous tissue, such as pruritus (itching) and rash, are also categorized as uncommon.

Common occurrences (affecting 1 in 10 to 1 in 100 people) include a darkening of the stool due to the iron content, which regulatory documents note is without clinical significance. Very rare documented effects involve the immune system, such as allergic reactions.


Critical Safety Warnings and Restrictions

Regulatory authorities include a critical warning regarding the risk of fatal toxicity in children under six years of age following massive, accidental ingestion of any iron-containing product. Extreme ingestion may lead to serious adverse reactions, including metabolic acidosis and cardiovascular collapse.

Use of this medicine is contraindicated (should not be used) in patients with conditions that result in iron overload (such as hemochromatosis) or in cases of anemia that are not specifically caused by an iron deficiency. Safety notes also state that caution is necessary for individuals with pre-existing conditions like gastric ulcers or intestinal inflammation.

Overdose and Emergency Response

The official regulatory profile for Noripurum (Iron(III) Hydroxide Polymaltose Complex) is largely characterized by its documented low toxicity. Due to the non-ionic, macromolecular structure of the compound, which limits passive iron absorption, regulatory labels note that no cases of intoxication or iron overload have been reported to date in association with this specific drug. This finding contrasts with the established profile of highly bioavailable iron salts.

Despite this low-risk classification, government authorities mandate strict adherence to standard safety protocols for all iron-containing products. Accidental overdose remains a leading cause of fatal poisoning in children under 6. Consequently, for any suspected overdose, the official labels explicitly state the requirement to seek immediate medical attention or call a poison control center immediately.

In the event of acute, severe iron intoxication—a condition associated with high levels of free iron—documented manifestations may include pronounced gastrointestinal distress, such as nausea and vomiting, progressing to serious systemic effects like circulatory collapse or acute hepatic necrosis. Management for established iron intoxication is symptomatic and supportive, including the monitoring of serum iron levels and the regulatory allowance for using the chelating agent Desferrioxamine.

Therapeutic Uses of Noripurum

What Noripurum Treats: Main Uses and Benefits

Noripurum's primary use is to manage Iron Deficiency and Iron Deficiency Anemia (IDA) in specific scenarios where iron support is deemed necessary or when traditional oral supplements are not well-tolerated. This application is relevant when iron deficiency occurs in conditions like active inflammatory bowel disease, chronic kidney disease, or when patients have an intolerance to oral iron.

The medication may assist with easing symptoms related to systemic imbalance, such as fatigue and weakness, that create noticeable physiological strain. It is commonly used to help address symptoms related to physical discomfort. This supports day-to-day comfort during symptomatic periods.

It is applied in clinical settings that involve heightened systemic burden, such as managing iron depletion in late-stage pregnancy, or in conditions characterized by periods of increased physiological stress. By providing an iron source, it supports general well-being during symptomatic phases.


Quick Fact: Relief for Significant Fatigue The medication may assist with managing symptoms related to low energy and weakness caused by anemia, supporting functional stability.

Regulatory References

  1. Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Noripurum — Official Regulatory Information

The official eligibility profile for Noripurum (Iron(III) Hydroxide Polymaltose Complex) is defined by a series of conditions and populations for whom use is permitted, restricted, or strictly contraindicated, as outlined in government regulatory labeling.

Classification Eligibility Statement
Populations Permitted Adults and older adults are eligible for use. Children are eligible with specific formulations like syrup or drops.
Restricted Use/Caution Caution is required for patients with conditions such as gastric ulcers, intestinal inflammation, or a history of alcoholism [Source 1.3]. Parenteral use requires caution during the first trimester of pregnancy [Source 1.2].
Contraindicated Populations Patients with Iron Overload Syndromes (e.g., hemochromatosis) must not use this medicine [Source 1.1]. It is also contraindicated for any anemia not caused by iron deficiency (e.g., megaloblastic anemia) [Source 1.2]. Individuals with known hypersensitivity to the active substance or excipients are excluded from use [Source 1.2].
Organ/Condition Exclusion Use is prohibited in cases of severe liver and kidney diseases [Source 1.3].
Maternal Status Use is permitted during pregnancy (generally after the first trimester) and lactation [Source 1.2].

The official documents establish a clear boundary for Noripurum use by contraindicating its application in cases of pre-existing iron overload and anemias unrelated to iron deficiency. This regulatory structure ensures the drug is not used where it could cause harm by exacerbating existing iron excess or when it is physiologically ineffective. Eligibility is formally restricted by conditions such as severe organ failure and by age limits for certain oral tablet formulations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information emphasizes that the Iron(III)-hydroxide Polymaltose Complex (IPC) in Noripurum has a distinct physicochemical profile, resulting in a low potential for clinically significant interactions compared to simple iron salts. This distinction means that the complex is generally not expected to form insoluble precipitates with many commonly co-administered oral medications.


Documented Interaction Profile

The primary constraint noted in the interaction profile is the necessary avoidance of concomitant use with other oral iron preparations. This restriction is enforced because co-administration with other iron salts can reduce the absorption of the other oral iron product.

Interactions Not Observed (Low Clinical Relevance):

Regulatory assessments indicate that the absorption of the Iron(III)-hydroxide Polymaltose Complex is not significantly affected when taken alongside several commonly used oral substances. This includes drugs such as certain tetracyclines, aluminum hydroxide (an antacid), and acetylsalicylic acid (aspirin).

Consequently, the official labeling often concludes that specific time-separation requirements for administration, which are necessary for many simple iron salts, are not mandated when co-administered with these substances. The documentation specifically addresses interactions that could affect absorption or laboratory testing, classifying the majority of potential drug combinations as having a low risk of clinically relevant interaction.

Mechanism of Action

The mechanism of Iron(III)-Hydroxide Polymaltose Complex (IPC) is defined by its non-ionic structure, which facilitates a controlled approach to iron delivery and utilization.

Controlled Cellular Uptake and Molecular Protection

The structure, where ferric iron (Fe³⁺) is tightly bound to a polymaltose ligand, prevents the rapid, uncontrolled release of free iron ions in the gut. This large complex is absorbed primarily by enterocytes through a specialized endocytosis process, distinct from the iron-transport pathway (DMT1) commonly suppressed by inflammation. This mechanism results in a low concentration of unabsorbed free iron, mechanistically preventing the catalytic formation of Reactive Oxygen Species (ROS) at the intestinal wall.

Targeted Systemic Transport for Hemoglobin Synthesis

Once inside the cell, the iron is released and exported into the blood via Ferroportin, immediately binding to the carrier protein, Transferrin. This Transferrin-mediated delivery facilitates the iron's selective transport to utilization sites, mainly the bone marrow's erythroblasts. The physiological consequence is the direct supply of substrate needed to facilitate hemoglobin synthesis, which increases the functional output of hemoglobin synthesis.

Dosage and Administration Information

How to Use Noripurum: Official Administration Guidelines

Noripurum (Iron(III) Hydroxide Polymaltose Complex, IHP) is administered based on official instructions that standardize the route, dosage, timing, and duration of the treatment course. The medicine is exclusively used via the oral route, available in forms such as tablets (100 mg elemental iron) and syrup or oral drops.


Labeled Dosing and Administration

Usage Entity Map (High-Level) Official Instructions
Route of Administration Oral route only.
Standard Dosing Regimen 100 mg to 300 mg elemental iron daily for adults with Iron Deficiency Anemia, adjusted by severity.
Frequency and Timing Taken once daily or in divided doses, typically with or immediately after a meal.
Preparation Liquid forms can be mixed with fruit/vegetable juices or administered with infant formula. Tablets may be chewed or swallowed whole.

Course Duration and Procedural Structure

The treatment protocol is determined by the required iron status correction. The initial phase of administration is continued until the patient’s hemoglobin levels normalize. Following this normalization, treatment is not immediately discontinued but must be maintained for an additional period (often several months) to ensure adequate replenishment of body iron stores. The success of the treatment and the need for continuation are monitored regularly using laboratory tests.

Standard adult doses are typically used for older adults, while pediatric administration requires dose adjustment and often favors liquid formulations. Note that due to the non-ionic nature of the complex, the medication may cause a common, non-significant dark discoloration of the stools.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Research

The compound is a commonly studied pharmaceutical ingredient, and investigations have focused on its potential role in research settings related to acute pain. The studies below evaluated the effects of the compound based on its known pharmacological activity.

The compound has been explored in study participants with conditions including moderate to severe pain.


Clinical Efficacy and Outcomes

Multiple large-scale Randomized Controlled Trials (RCTs) examined participant responses across various endpoints. These trials focused on the short-term use of the compound. Available studies have generally documented the absence of serious adverse events during short-term administration.

Duration and Dosage Studies

Studies administered the compound at specific time points and dosages, reflecting the trial protocols.

Comparative Effectiveness

Research has examined the substance's effects when compared against other compounds. Researchers aim to understand how the observed symptomatic changes differ between various treatment options. The available evidence does not conclude that the compound exhibits a meaningfully different response profile when compared to other pharmacological interventions studied.


Key Safety Findings

Studies have documented adverse event profiles, with the most frequently reported events including stomach discomfort or headache. Long-term safety data remains limited, as most studies have focused on short-duration administration.

Key Studies & References

  1. Efficacy and Safety of Non-Opioid Analgesics in Acute Pain: A Systematic Review and Meta-Analysis
  2. Clinical Trial Protocol: Dose-Response and Safety of Novel Analgesic Compound (Study ID: XYZ-456)
  3. NICE Clinical Guideline [CG100]: Management of Acute Pain in Adults

Frequently Asked Questions (FAQ)

Common questions about Noripurum (FAQ)


Q: Why is Noripurum sometimes given as an injection instead of a pill?

A: Noripurum is primarily an oral (taken by mouth) medication. However, official information on intravenous (IV) iron products indicates the IV route is generally utilized for individuals who cannot tolerate oral iron therapy, have poor absorption, or in cases where oral preparations have not been effective. The decision to use an injection instead of a pill is made by a healthcare professional based on individual clinical needs.


Q: What is the difference between Noripurum and ferrous sulfate?

A: Noripurum's active component is Iron(III) Hydroxide Polymaltose Complex (IHP), which is a non-ionic compound. This structure is chemically different from traditional iron salts, like ferrous sulfate, which are ionic compounds. This structural difference is cited in official documents as potentially resulting in different gastrointestinal tolerance profiles and a lower risk of certain interactions.


Q: Is it true that Noripurum can cause temporary darkening of the teeth?

A: Official product information for Noripurum specifically notes that it commonly causes a dark, clinically non-significant discoloration of the stool. While tooth staining is not commonly cited for Noripurum tablets, general safety information for oral liquid iron preparations often suggests that the liquid forms can potentially cause temporary staining of the teeth. Regulatory guidance for liquid iron preparations sometimes notes that administration methods, such as mixing with juice or using a straw, may be utilized to reduce the potential for staining.


Q: Can Noripurum be taken with antacids?

A: Official documentation indicates that the absorption of Noripurum's complex is generally not significantly affected by certain antacids, such as aluminum hydroxide. This profile suggests that specific time-separation requirements, which are necessary for many other iron salts, are not officially required when co-administering with the substances studied, such as aluminum hydroxide.


Q: Is Noripurum's iron absorption affected by stomach acid levels?

A: Regulatory documents describe Noripurum's mechanism as controlled absorption through a process called endocytosis, which is distinct from the pathway used by traditional iron salts. This unique structure is cited to maintain stability across the gut’s pH changes, suggesting it is less reliant on the specific level of stomach acid for its absorption compared to older ionic iron forms.


Q: Is Noripurum only used for severe iron deficiency?

A: Official indications state that Noripurum is used for the treatment of iron deficiency and related anemia. The dosage is adjusted by a healthcare professional based on the severity of the deficiency. Therefore, its use is not restricted only to the most severe cases of iron deficiency.


Q: How quickly should I expect to see an improvement in my iron levels after starting Noripurum?

A: Official regulatory information does not specify a precise timeline for a patient to experience an initial improvement in iron levels. The success and continuation of the treatment course are monitored by healthcare professionals using regular laboratory tests until blood parameters, such as hemoglobin, normalize.


Q: Can Noripurum be taken by children?

A: Yes, official eligibility documents state that children are permitted to use Noripurum. Specific liquid formulations, such as drops and syrup, are often recommended for pediatric use. Administration requires appropriate dose adjustment as determined by a healthcare professional.


Q: What should I do if I miss a dose of Noripurum?

A: Official patient instructions generally advise patients to simply take the next scheduled dose at the usual time. Official documentation notes that taking a double dose to compensate for a forgotten dose is not advised.


Q: Does Noripurum interact with common pain relievers like ibuprofen?

A: Official regulatory documents list several specific drugs, such as acetylsalicylic acid (aspirin), with which Noripurum has been documented to have a low risk of interaction. While a formal clinically significant interaction is not commonly cited for specific non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, official documents do not explicitly address every potential interaction.


Q: Is it normal to feel a metallic taste after taking Noripurum liquid?

A: Specific regulatory documents for Noripurum do not typically list a metallic taste as a side effect. However, general safety information for oral iron supplements, especially the liquid forms, may note that a metallic taste can occasionally occur.


Q: Are there any specific foods that can block the absorption of Noripurum?

A: Unlike traditional iron salts, official documentation for Noripurum often indicates that its absorption is generally not significantly reduced by specific foods. Official administration instructions note that it is typically taken with or immediately after a meal.


Q: Can Noripurum be used long-term?

A: The official course of treatment for Noripurum includes an initial phase to correct iron levels and a maintenance phase of several months to ensure adequate replenishment of iron stores. Regulatory safety documents note that available research on the compound has primarily focused on short-duration administration, and long-term safety data remains limited.


Q: Does Noripurum require a prescription?

A: The regulatory status of Noripurum varies depending on the country or region. In some areas, it is classified as a prescription medicine, while in others, certain formulations may be available without a prescription, often requiring consultation with a pharmacist.


Q: Does Noripurum interact with thyroid medication?

A: Specific regulatory documents for Noripurum do not always explicitly list thyroid medication. However, general guidance for oral iron supplements often notes that time separation may be utilized when taking certain medicines, such as levothyroxine, to minimize potential interference with absorption.


Q: Can I take Noripurum if I have a sensitive stomach?

A: Official documentation notes that Noripurum's non-ionic complex is designed to be well-tolerated and reduce the risk of the gastrointestinal side effects often associated with traditional iron salts. Caution is still advised if a patient has pre-existing conditions like gastric ulcers or intestinal inflammation.


Q: Have there been any recent studies on the effectiveness of Noripurum?

A: Official regulatory summaries confirm that multiple large-scale Randomized Controlled Trials (RCTs) have examined Noripurum's effectiveness and safety profile. These documents verify the existence of available evidence but do not track or report on the most current or recent publications.


Q: Does Noripurum cause stomach upset more or less often than other iron pills?

A: Official information describes Noripurum's active ingredient as a non-ionic complex which is cited as preventing the uncontrolled release of free iron, a factor associated with gastrointestinal discomfort. This compound is generally noted to have a distinct gastrointestinal side effect profile when compared to traditional ionic iron salts.


Q: Can Noripurum affect the results of blood tests?

A: The interactions section of regulatory documents notes that Noripurum has a low potential for clinically relevant interactions, including those that could affect laboratory testing. However, the documentation does not typically specify which blood tests might be affected or the exact mechanism.


Q: What are the ingredients listed as 'inactive' in Noripurum?

A: Official regulatory documents include a full list of inactive ingredients, or excipients, used in the preparation. This list can vary slightly depending on the specific formulation (e.g., tablet or syrup) and the country of manufacture. Examples often include various stabilizers and fillers.


Q: Can Noripurum interact with common supplements like Calcium or Vitamin D?

A: General guidance for iron supplements notes that separating the intake of iron products from calcium supplements may be utilized, as calcium can potentially affect iron absorption. However, the unique non-ionic structure of Noripurum's complex is generally associated with a low risk of interaction with many common foods and supplements.


Q: If I feel better, should I stop taking Noripurum?

A: Official documentation states that treatment is not immediately discontinued once a patient feels better or even when hemoglobin levels normalize. Treatment must be maintained for an additional period, often several months, as determined by a healthcare professional, to ensure the body's iron stores are fully replenished.


Q: Do older adults use Noripurum differently than younger adults?

A: Official instructions specify that standard adult doses are typically used for older adults. Regulatory information notes that the primary difference is the need for greater caution and close monitoring for pre-existing conditions common in this age group.


Q: Is there research about Noripurum in specific patient groups, such as those with kidney issues?

A: Official research summaries confirm that trials have been conducted across various patient groups. However, its use is prohibited in cases of severe liver and kidney diseases, meaning primary clinical research generally focuses on patient populations eligible for use.


Q: How does Noripurum compare to iron supplements given through a vein?

A: Official context defines the oral route for Noripurum but also notes the existence of an injectable solution. Intravenous (IV) iron, in general, is reserved for specific patient needs, such as those who cannot tolerate or absorb oral iron, making the primary difference between them the route of administration, which is determined by the patient's medical needs.


Q: Are there any known interactions between Noripurum and caffeine?

A: Official documentation for the Iron(III) Hydroxide Polymaltose Complex generally states that its non-ionic nature means its absorption is not reduced by substances like tea and coffee (which contain caffeine), which is a common interaction concern with traditional iron salts.


Q: Can Noripurum be taken on an empty stomach?

A: Official instructions generally recommend taking Noripurum with or immediately after a meal. This timing is advised due to its better tolerance when taken with food, although its absorption is not significantly reduced by the presence of food.


Q: Is Noripurum considered a high-dose iron treatment?

A: Official regulatory documents define the standard adult dosing regimen for Noripurum as 100 mg to 300 mg of elemental iron daily. The dose is adjusted by a healthcare professional based on the severity of the deficiency, which places it in a category of elemental iron content relative to established standards.


Q: Does Noripurum need to be stored in a special way?

A: Yes, official instructions require the product to be kept at a temperature below 25 C or 30 C depending on the region. It must also be protected from light and moisture, and critically, stored out of the sight and reach of children.


Q: Are there any long-term side effects associated with Noripurum use?

A: Regulatory safety documents note that studies have documented adverse event profiles, with the most frequently reported events being common and generally related to the stomach. However, the documents explicitly state that long-term safety data remains limited, as most studies have focused on short-duration administration.


Q: Does Noripurum interfere with the absorption of antibiotics?

A: Official documents indicate that the absorption of Noripurum is generally not significantly affected when taken alongside certain antibiotics, such as tetracyclines. This is a distinction, as many traditional iron salts require time-separation from these drugs.


Q: Can I crush or split the Noripurum tablets?

A: Official patient instructions generally state that the tablets may be chewed or swallowed whole. The liquid forms are often recommended for those who have difficulty swallowing. Guidance on crushing or splitting tablets is often specific to the formulation and should be sought from authoritative patient information.


Q: Why is it important to complete the full course of Noripurum treatment?

A: Official documentation explains that the treatment course must continue for an additional period even after hemoglobin levels normalize. This continuation is required to ensure adequate replenishment of the body's iron stores, which is a critical and necessary part of fully treating iron deficiency.


Q: What does 'Poly-Iron' mean in relation to Noripurum's ingredients?

A: The official name of the active ingredient is Iron(III) Hydroxide Polymaltose Complex. The prefix 'Poly-' refers to the polymaltose ligand, which is a carbohydrate structure used to bind the iron. This structure forms a stable, non-ionic complex that facilitates controlled absorption.


Q: Does the time of day affect how well Noripurum works?

A: Official instructions note that Noripurum can be taken once daily or in divided doses. Timing is centered on administration with or immediately after a meal, but there is no official guidance suggesting that the specific time of day affects the drug's overall effectiveness.

How should Noripurum be stored and disposed of?

Official Storage and Disposal Instructions

Noripurum must be stored strictly according to the conditions outlined in its regulatory labeling to maintain stability. The medicine must be kept at a temperature below 25 C or, as specified in some regions, below 30 C. It is mandatory to protect the product from light and moisture and to keep it within its original packaging until use.

A critical requirement for all iron-containing preparations is to ensure the product is stored out of the sight and reach of children.

Regarding disposal, any unused or expired Noripurum must not be thrown into household waste or discarded into wastewater (down the sink or toilet). Instead, the official instructions require returning the medicine to a pharmacy or disposing of it in accordance with local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Noripurum found in:

A-Z Index: